Literature DB >> 18595147

Pathologic complete response confirmed by surgical resection for liver metastases of gastrointestinal stromal tumor after treatment with imatinib mesylate.

Seiji Suzuki1, Koji Sasajima, Masayuki Miyamoto, Hidehiro Watanabe, Tadashi Yokoyama, Hiroshi Maruyama, Takeshi Matsutani, Aimin Liu, Masaru Hosone, Shotaro Maeda, Takashi Tajiri.   

Abstract

A 39-year-old male underwent distal gastrectomy for a high grade gastrointestinal stromal tumor (GIST). Computed tomography (CT) and magnetic resonance imaging (MRI) 107 mo after the operation, revealed a cystic mass (14 cm in diameter) and a solid mass (9 cm in diameter) in the right and left lobes of the liver, respectively. A biopsy specimen of the solid mass showed a liver metastasis of GIST. The patient received imatinib mesylate (IM) treatment, 400 mg/day orally. Following the IM treatment for a period of 35 mo, the patient underwent partial hepatectomy (S4 + S5). The effect of IM on the metastatic lesions was interpreted as pathologic complete response (CR). Pathologically verified cases showing therapeutic efficacy of IM have been rarely reported.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18595147      PMCID: PMC2719243          DOI: 10.3748/wjg.14.3763

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  17 in total

1.  Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.

Authors:  H Joensuu; P J Roberts; M Sarlomo-Rikala; L C Andersson; P Tervahartiala; D Tuveson; S Silberman; R Capdeville; S Dimitrijevic; B Druker; G D Demetri
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

2.  First report of a complete pathological response of a pelvic GIST treated with imatinib as neoadjuvant therapy.

Authors:  M Salazar; A Barata; S André; J Venâncio; I Francisco; M Cravo; C Nobre-Leitão
Journal:  Gut       Date:  2006-04       Impact factor: 23.059

3.  Surgery including liver resection for metastatic gastrointestinal stromal tumors or gastrointestinal leiomyosarcomas.

Authors:  Souya Nunobe; Tsuyoshi Sano; Kazuaki Shimada; Yoshihiro Sakamoto; Tomoo Kosuge
Journal:  Jpn J Clin Oncol       Date:  2005-05-31       Impact factor: 3.019

4.  Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib.

Authors:  Sebastian Bauer; Jörg Thomas Hartmann; Maike de Wit; Hauke Lang; Florian Grabellus; Gerald Antoch; Wolfgang Niebel; Jochen Erhard; Peter Ebeling; Matthias Zeth; Georg Taeger; Siegfried Seeber; Michael Flasshove; Jochen Schütte
Journal:  Int J Cancer       Date:  2005-11-01       Impact factor: 7.396

5.  Results of hepatic resection for sarcoma metastatic to liver.

Authors:  R P DeMatteo; A Shah; Y Fong; W R Jarnagin; L H Blumgart; M F Brennan
Journal:  Ann Surg       Date:  2001-10       Impact factor: 12.969

6.  Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era.

Authors:  S Bonvalot; H Eldweny; C Le Péchoux; D Vanel; P Terrier; A Cavalcanti; C Robert; N Lassau; A Le Cesne
Journal:  Ann Surg Oncol       Date:  2006-12       Impact factor: 5.344

7.  Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST.

Authors:  Alessandro Gronchi; Marco Fiore; Francesca Miselli; Maria Stefania Lagonigro; Paola Coco; Antonella Messina; Silvana Pilotti; Paolo Giovanni Casali
Journal:  Ann Surg       Date:  2007-03       Impact factor: 12.969

8.  Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor.

Authors:  Ronald P DeMatteo; Robert G Maki; Samuel Singer; Mithat Gonen; Murray F Brennan; Cristina R Antonescu
Journal:  Ann Surg       Date:  2007-03       Impact factor: 12.969

9.  Surgical resection of gastrointestinal stromal tumors after treatment with imatinib.

Authors:  Robert H I Andtbacka; Chaan S Ng; Courtney L Scaife; Janice N Cormier; Kelly K Hunt; Peter W T Pisters; Raphael E Pollock; Robert S Benjamin; Michael A Burgess; Lei L Chen; Jonathan Trent; Shreyaskumar R Patel; Kevin Raymond; Barry W Feig
Journal:  Ann Surg Oncol       Date:  2007-01       Impact factor: 5.344

10.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

Authors:  George D Demetri; Margaret von Mehren; Charles D Blanke; Annick D Van den Abbeele; Burton Eisenberg; Peter J Roberts; Michael C Heinrich; David A Tuveson; Samuel Singer; Milos Janicek; Jonathan A Fletcher; Stuart G Silverman; Sandra L Silberman; Renaud Capdeville; Beate Kiese; Bin Peng; Sasa Dimitrijevic; Brian J Druker; Christopher Corless; Christopher D M Fletcher; Heikki Joensuu
Journal:  N Engl J Med       Date:  2002-08-15       Impact factor: 91.245

View more
  4 in total

1.  Pathologic complete response with neoadjuvant imatinib for locally advanced pelvic GIST.

Authors:  Carla Rameri Alexandre Silva de Azevedo; Tadeu Ferreira Paiva; Benedito Mauro Rossi; Gustavo Cardoso Guimarães; Maria Dirlei Ferreira de Souza Begnami; Thiago Bueno Oliveira; Milton José Barros E Silva; Marcello Ferretti Fanelli; Celso Abdon Lopes de Mello
Journal:  Int J Clin Oncol       Date:  2010-10-05       Impact factor: 3.402

Review 2.  Gastrointestinal stromal tumours at present: an approach to burning questions.

Authors:  Manuel García de Polavieja Carrasco; Ana de Juan Ferré; Marta Mayorga Fernández
Journal:  Clin Transl Oncol       Date:  2010-02       Impact factor: 3.405

Review 3.  Rare cystic liver lesions: a diagnostic and managing challenge.

Authors:  Andreas Bakoyiannis; Spiros Delis; Charina Triantopoulou; Christos Dervenis
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

4.  Pathological complete response in advanced gastric stromal tumor after imatinib mesylate therapy: a case report.

Authors:  Omar El Mesbahi; Sami Aziz Brahmi; Yousra Akasbi; Fatima Zahra El Mrabet; Anas Touyar; Abdelmalek Ossaden; Kaoutar Znati; Khalid Maazaz; Affaf Amarti; Siham Tizniti; Khalid Ait Taleb; Adil Ibrahimi
Journal:  J Med Case Rep       Date:  2011-05-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.